High-linear energy transfer (LET) α versus low-LET β emitters in radioimmunotherapy of solid tumors: Therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1a Fab' fragments in a human colonic cancer model

Cancer Research

Volumn 59, Issue 11, 1999, Pages 2635-2643

  Behr, Tomas M ^a   Béhé, Martin ^a   Stabin, Michael G ^b   Wehrmann, Eike ^a   Apostolidis, Christos ^c   Molinet, Roger ^c   Strutz, Frank ^a   Fayyazi, Afshin ^a   Wieland, Eberhard ^a   Gratz, Stefan ^a   Koch, Lothar ^c   Goldenberg, David M ^d   Becker, Wolfgang ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^c JOINT RESEARCH CENTRE   (Italy)

^d GARDEN STATE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH; EDRECOLOMAB; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CANCER TRANSPLANTATION; COLON CANCER; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MAXIMUM ALLOWABLE CONCENTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BISMUTH; BONE AND BONES; COLONIC NEOPLASMS; FEMALE; HALF-LIFE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; KIDNEY; LINEAR ENERGY TRANSFER; MICE; MICE, NUDE; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RELATIVE BIOLOGICAL EFFECTIVENESS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; YTTRIUM RADIOISOTOPES;

EID: 0344326255     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Goldenberg, D. M. (ed.). Cancer Therapy with Radiolabeled Antibodies. Boca Raton, FL: CRC Press, 1995.
2. 131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med., 329: 459-465, 1993.
3. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphoma. Lancet, 346: 336-340, 1995.
4. 131I-labeled anti-CEA murine IgG monoclonal antibody. J. Nucl. Med., 38: 858-870, 1997.
5. Behr, T. M., Sharkey, R. M., Juweid, M. E., Dunn, R. M., Siegel, J. A., and Goldenberg, D. M. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of CEA-expressing tumors. Cancer Res., 56: 1805-1816, 1996.
6. 125I-labeled monoclonal antibody 17-la in human cancer cells. Cancer Res., 49: 2952-2958, 1989.
7. 131I-labeledCO17-l A in a human colorectal cancer model. Int. J. Cancer, 76: 738-748, 1998.
8. Meredith, R. F., Khazaeli, M. B., Plott W. E., Spencer, S. A., Wheeler R. H., Brady, L. W., Woo, D. V., and LoBuglio, A. F. Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J. Nucl. Med., 36: 2229-2233, 1995.
9. Welt, S., Scott, A. M., Divgi, C. R., Kemeny, N. E., Finn, R. D., Daghighian, F., St. Germain, J., Richards, E. C., Larson, S. M., and Old, L. J. Phase I/II study of iodine-125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. Clin. Oncol., 14: 1787-1797, 1996.
10. 2 fragments with the α-particle-emitting nuclide astatine-211: preservation of ist immunoreactivily and in vivo localizing capacity. Proc. Natl. Acad. Sci. USA, 86: 7149-7153, 1989.
11. McDevitt, M. R., Sgouros, G., Finn, R. D., Humm, J. L., Jurcic, J. G., Larson, S. M., and Scheinberg, D. A. Radioimmunotherapy with α-emitting nuclides. Eur. J. Nucl. Med., 25: 1341-1351, 1998.
12. Zalutsky, M. R., and Narula, A. S. Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate. Int. J. Radiat. Appl. Instrum. A, 39: 227-232, 1988.
13. 2 fragment labeled with N-succinimidyl-2,4-dimethoxy-3-halobenzoates: in vivo comparison of iodinated and astatinated fragments. Nucl. Med. Biol., 21: 105-110, 1994.
14. Macklis, R. M., Kinsey, B. M., Kassis, A. L., Ferrara, J. L. M., Atcher, R. W., Hines, J. J., Coleman, C. N., Adelstein, S. J., and Burackhoff, S. J. Radioimmunotherapy with α-particle-emitting immunoconjugates. Science (Washington DC), 240: 1024-1026, 1988.
15. Kurtzman, S. H., Russo, A., Mitchell, J. B., DeGraff, W., Sindelar, W. F., Brechbiel, M. W., Gansow, O. A., Friedman, A. M., Hines, J. J., Gamson, J., and Atcher, R. W. Bismuth-212 linked to an antipancreatic carcinoma antibody: model for α-particleemitter radioimmunotherapy. J. Natl. Cancer Inst. (Bethesda), 80: 449-452, 1988.
16. 225Ac as a source of α-particles in radioimmunotherapy. Nucl. Med. Commun., 14: 121-125, 1993.
17. 225Ac-immunoconjugates. Nucl. Med. Commun., 16: 468-476, 1995.
18. 90Y. Int. J. Radiat. Oncol. Biol. Phys., 10: 341-348, 1984.
19. Behr, T. M., Memtsoudis, S., Sharkey, R. M., Blumenthal, R. D., Dunn, R. M., Gratz, S., Wieland, E., Nebendahl, K., Schmidberger, H., Goldenberg, D. M., and Becker, W. Experimental studies on the role of antibody fragments in cancer radioimmunotherapy: influence of radiation dose and dose rate on toxicity and antitumor efficacy. Int. J. Cancer, 77: 787-795, 1998.
20. Behr, T. M., Sharkey, R. M., Juweid, M. E., Blumenthal, R. D., Dunn, R. M., Bair, H. J., Griffiths, G. L., Wolf, F. G., Becker, W. S., and Goldenberg, D. M. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res., 55: 3825-3834, 1995.
21. Behr, T. M., Sharkey, R. M., Sgouros, G., Blumenthal, R. D., Dunn, R. M., Kolbert, K., Griffiths, G. L., Siegel, J. A., Becker, W. S., and Goldenberg, D. M. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer (Phila.), 80: 2591-2610, 1997.
22. Herlyn, M., Steplewski, Z., Herlyn, D., and Koprowski, H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc. Natl. Acad. Sci. USA, 76: 1438-1442, 1979.
23. Koprowski, H., Steplewski, Z., Mitchell, K., Herlyn, M., Herlyn, D., and Fuhrer, J. P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat. Cell Genet., 5: 957-972, 1979.
24. Gottlinger, H. G., Funke, I., Johnson, J. P., Gokel, J. M., and Riethmüller, G. The epithelial surface antigen 17-1A, a target for antibody-mediated tumour therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int. J. Cancer, 38: 47-53, 1986.
25. Brechbiel, M. W., Gansow, O. A., Achter, R. W., Schlom, J., Esteban, J. M., Simpson, D. E., and Colcher, D. Synthesis of 1-(p-isothiocyanobenzyl) derivatives of DTPA and EDTA: antibody labeling and tumor imaging studies. Inorg. Chem., 25: 2772-2781, 1986.
26. Spivakov, B. Y., Stoyanov, E. S., Gribov, L. A., and Zolotov, Y. A. Raman laser spectroscopic studies of bismuth(III) halide complexes in aqueous solutions. J. Inorg. Nucl. Chem., 41: 453-455, 1979.
27. 213Bi for α-particle-mediated radioimmunotherapy. J. Lab. Comput. Radiopharm., XL: 341, 1997.
28. Van Geel, J. N. C., Fuger, J., and Koch, L. Verfahren zur Erzeugung von Actinium-225 und Wismuth-213, European Patent No. 0 443 479 B1, 1994.
29. Goldenberg, D. M., Witte, S., and Elster, K. GW-39: a new human tumor serially transplantable in the golden hamster. Transplantation (Baltimore), 4: 760-764, 1966.
30. Yoriyaz, H., and Stabin, M. Electron and photon transport in a model of a 30g mouse. J. Nucl. Med., 38: 228P, 1997.
31. Briesmeister, J. MCNP: A General Monte Carlo n-Particle Transport Code. MCNP User's Manual. Los Alamos, NM: Los Alamos National Laboratory, 1993.
32. Behr, T. M., Sgouros, G., Stabin, M. G., Béhé, M., Angerstein, C., Blumenthal, R. D., Apostolidis, C., Molinet, R., Sharkey, R. M., Koch, L., Goldenberg, D. M., and Becker, W. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with β-, Auger/conversion electron-, or α-emitters. Clin. Cancer Res., in press, 1999.
33. Blumenthal, R. D., Sharkey, R. M., Forman, D., Wong, G., Hess, J., and Goldenberg, D. M. Improved experimental cancer therapy by radioantibody dose intensification as a result of syngeneic bone marrow transplantation. Exp. Hematol., 23: 1088-1097, 1995.
34. Sharkey, R. M., Blumenthal, R. D., Behr, T. M., Wong, G. Y., Haywood, L., Forman, D., Griffiths, G. L., and Goldenberg, D. M. Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. Int. J. Cancer, 72: 477-485, 1997.
35. Wilcoxon, F. Individual comparisons by ranking methods. Biometrics, 1: 80-83, 1945.
36. Sprent, P. Applied Nonparametric Statistical Methods, Ed. 2. London: Chapman & Hall, 1993.
37. Bowalekar, S. K. Statistics in medical research: IV. Sampling distribution, statistical testing of hypothesis and Student's r-test. J. Postgrad. Med., 40: 46-51, 1994.
38. Behr, T. M., Sgouros, G., Sharkey, R. M., Dunn, R. M., Blumenthal, R. D., Kolbert, K., Siegel, J. A., and Goldenberg, D. M. Y-90-dosimetry in nude mice requires accounting for cross-organ radiation: evaluation of three dosimetry models in relation to observed biological effects. J. Nucl. Med., 37: 102P, 1996.
39. Sgouros, G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J. Nucl. Med., 34: 689-694, 1993.
40. Behr, T. M., Wulst, E., Radetzky, S., Blumenthal, R. D., Dunn, R. M., Gratz, S., Rave-Fränk, M., Schmidberger, H., Raue, F., and Becker, W. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res., 57: 5309-5319, 1997.
41. Wu, C., Kobayashi, H., Sun, B., Yoo, T. M., Paik, C. H., Gansow, O. A., Carrasquillo, J. A., Pastan, I., and Brechbiel, M. W. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg. Med. Chem., 5: 1925-1934, 1997.
42. Ruegg, C. L., Anderson-Berg, W. T., Brechbiel, M. W., Mirzadeh, S., Gansow, O. A., and Strand, M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res., 50: 4221-4226, 1990.
43. 212Bi-anti-Tac. Cancer Res., 54: 4362-4370, 1994.
44. Hendry, J. H., and Lord, B. I. (eds.). Radiation Toxicology: Bone Marrow and Leukaemia. London: Taylor & Francis, 1995.
45. Hall, E. J. Radiobiology for the Radiologist. Philadelphia: J. B. Lippincott, 1994.
46. Walden Jr, T. L., and Farzaneh, N. K. Biochemistry of Ionizing Radiation. New York: Raven Press, 1990.
47. Howell, R. W., Azure, M. T., Narra, V. R., and Rao, D. V. Relative biological effectiveness of α-emitters in vivo at low doses. Radiat. Res., 137: 352-360, 1994.
48. Howell, R. W., Goddu, S. M., Narra, V. R., Fisher, D. R., Schenter, R. E., and Rao, D. V. Radiotoxicity of gadolinium-148 and radium-223 in mouse testes: relative biological effectiveness of α-particle emitters in vivo. Radiat. Res., 147: 342-348, 1997.
49. Charlton, D. E., Utteridge, T. D., and Allen, B. J. Theoretical treatment of human haemopoietic stem cell survival following irradiation by α particles. Int. J. Radiat. Biol., 74: 111-118, 1998.
50. Jurcic, J. G., McDevitt, M. R., Sgouros, G., Ballangrud. Å., Finn, R. D., Geerlings, M. W., Humm, J. L., Molinet, R., Apostolidis, C., Larson, S. M., and Scheinberg, D. A. Targeted α-particle therapy for myeloid leukemias: a Phase I trial of bismuth213-HuM195 (anti-CD33). Blood, 90 (Suppl.): 504a, 1997.
51. Behr, T. M., Goldenberg, D. M., and Becker, W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur. J. Nucl. Med., 25: 201-212, 1998.
52. Behr, T. M., Salib, A., Gratz, S., Béhé, M., Yücekent, S., Blumenthal, R. D., Sharkey, R. M., Goldenberg, D. M., and Becker, W. Radioimmunotherapy of colorectal cancer in small volume disease: evaluation of radioimmunotherapy versus standard chemotherapy in a nude mouse model of human colon cancer metastatic to the liver. Eur. J. Nucl. Med., 25: 894, 1998.